Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if QNCX is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
6 top institutions tracked
Sentiment: unknown
No recent insider trades detected.
Red flags: 13
26 filers reported a long position in QNCX for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
Q1 2026 shares are adjusted for the 2026-04-13 1-for-10 reverse split, 2026-06-30 1-for-20 reverse split.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| BALYASNY ASSET MANAGEMENT L.P. | $12.6M | 70K | New |
| Ikarian Capital, LLC | $1.3M | 72.3K | New |
| MILLENNIUM MANAGEMENT LLC | $1.3M | 70.8K | +465.4% |
| Squadron Capital Management LLC | $734.4K | 40.4K | New |
| Shay Capital LLC | $329.3K | 17.5K | +97.1% |
| BOOTHBAY FUND MANAGEMENT, LLC | $253K | 13.9K | New |
| JANE STREET GROUP, LLC | $230K | 12.6K | New |
| VANGUARD CAPITAL MANAGEMENT LLC | $219.1K | 12K | +422% |
| Cormorant Asset Management, LP | $100K | 5.5K | New |
| UBS Group AG | $86K | 4.7K | +170,043.9% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.